WHAT IS KNOWN AND OBJECTIVE: Hypertriglyceridaemia (HTG) is a potentially serious side effect of everolimus therapy. We here report a case of severe HTG in an everolimus-treated patient and provide recommendations for its management. CASE SUMMARY: The patient was a 70-year-old woman, being treated with everolimus for a pancreatic neuroendocrine tumour (pNET). She developed severe HTG to a maximum of 969 mg/dL after 22 months of therapy. Treatment with fenofibrate rapidly normalized triglyceride (TG) levels. WHAT IS NEW AND CONCLUSION: Severe HTG may occur in everolimus-treated patients. Prescription of the appropriate therapy can allow patients to continue this medication.
Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET) / V. De Gennaro Colonna, C. Pavanello, F. Rusconi, A. Sartore-Bianchi, S. Siena, S. Castelnuovo, C.R. Sirtori, G. Mombelli. - In: JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS. - ISSN 1365-2710. - 43:1(2018), pp. 114-116. [10.1111/jcpt.12588]
Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET)
V. De Gennaro Colonna;C. Pavanello;A. Sartore-Bianchi;S. Siena;S. Castelnuovo;C.R. Sirtori;G. Mombelli
2018
Abstract
WHAT IS KNOWN AND OBJECTIVE: Hypertriglyceridaemia (HTG) is a potentially serious side effect of everolimus therapy. We here report a case of severe HTG in an everolimus-treated patient and provide recommendations for its management. CASE SUMMARY: The patient was a 70-year-old woman, being treated with everolimus for a pancreatic neuroendocrine tumour (pNET). She developed severe HTG to a maximum of 969 mg/dL after 22 months of therapy. Treatment with fenofibrate rapidly normalized triglyceride (TG) levels. WHAT IS NEW AND CONCLUSION: Severe HTG may occur in everolimus-treated patients. Prescription of the appropriate therapy can allow patients to continue this medication.File | Dimensione | Formato | |
---|---|---|---|
2017 De Gennaro Colonna et al, Journal_of_Clinical_Pharmacy_and_Therapeutics.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
232.44 kB
Formato
Adobe PDF
|
232.44 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Colonna_et_al-2018-Journal_of_Clinical_Pharmacy_and_Therapeutics.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
313.46 kB
Formato
Adobe PDF
|
313.46 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.